F-1: IceCure Medical Launches $10 Million Rights Offering to Fund Operations and Repay Bridge Loan Amidst FDA Review and Geopolitical Risks

Sentiment:

Rights Offering Registration Statement 16 June 2025 8:19 AM

IceCure Medical Ltd. has filed an F-1 registration statement for a non-transferable rights offering aiming to raise up to $10 million to repay a bridge loan and support general corporate and working capital needs, while awaiting final FDA marketing authorization for its ProSense system.

Delay expectedThe FDA requested that IceCure conduct a post-market study after marketing authorization has been granted for ProSense, which is expected to include a minimum of 400 patients at 25 sites. The FDA's final marketing authorization decision is expected only upon the CDRH's approval of this post-market study plan, indicating a delay in the final marketing authorization.Ongoing multi-front conflict in Israel, including the resumption of hostilities with Hamas, a preemptive strike on Iran, and temporary closures of Israeli airspace and port activity, may lead to significant delays or diversions of components for manufacturing and production, potentially resulting in supply limitations and delayed shipments to customers.The call-up of Israeli military reservists, including company employees, could disrupt operations, as such persons may be absent for extended periods.

Capital raiseThe company is distributing non-transferable subscription rights to existing shareholders to purchase up to an aggregate of units for gross proceeds of up to $10,000,000.Each unit consists of one Ordinary Share and a warrant to purchase one Ordinary Share, or one Pre-Funded Warrant and one Warrant.The subscription price per unit is unspecified, but the last sale price of Ordinary Shares on Nasdaq was $0.97 per share as of June 13, 2025.Epoch Partner Investments Limited has committed to participate in the Rights Offering by exercising its Basic Subscription Rights in full and Over-Subscription Privileges to purchase unsubscribed shares with an aggregate Subscription Price of up to $5,000,000.The company entered into a $2,000,000 unsecured bridge loan agreement with Epoch on May 17, 2025, which is intended to be repaid using proceeds from this equity transaction.

Summary

IceCure Medical Ltd. is conducting a non-transferable rights offering to raise up to $10,000,000 in gross proceeds by distributing subscription rights to existing ordinary shareholders.
Each shareholder will receive one subscription right for every ordinary share owned, entitling them to purchase one unit consisting of one ordinary share and one warrant, or one pre-funded warrant and one warrant, at an unspecified subscription price.
The company intends to use the net proceeds, estimated at approximately $9.4 million if fully subscribed, along with existing cash, to repay a $2,000,000 bridge loan from Epoch Partner Investments Limited and for general corporate and working capital purposes.
Epoch Partner Investments Limited, which beneficially owns approximately 44.04% of IceCure's ordinary shares, has committed to participate in the offering by exercising its basic subscription rights in full and over-subscription privileges up to an aggregate subscription price of $5,000,000.
As of March 31, 2025, IceCure had an accumulated deficit of $109.0 million and cash and cash equivalents of $6.0 million.
The company expects the proceeds from this offering to fund operations and capital expenditure requirements through May 31, 2026, but will require additional capital thereafter.
The FDA Advisory Panel voted favorably on November 7, 2024, for the benefits of ProSense for early-stage low-risk invasive breast cancer, but the FDA has requested a post-market study of at least 400 patients at 25 sites after marketing authorization is granted, delaying a final decision.
The subscription rights are non-transferable, and there is no established public trading market for the pre-funded warrants or warrants being issued.
The offering involves significant dilution risk for shareholders who do not fully exercise their rights, especially given Epoch's standby commitment.
The company's operations are significantly exposed to political, economic, and military instability in Israel, including ongoing conflicts and potential disruptions to supply chains and employee availability.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the FDA advisory panel's favorable vote is positive, the subsequent request for a post-market study delays final marketing authorization. The capital raise is necessary but highlights the company's significant accumulated deficit and ongoing need for funding. Geopolitical risks in Israel add substantial uncertainty and potential operational disruptions.

Positives

The FDA Medical Device Advisory Committee Panel voted favorably on November 7, 2024, that the benefits of the ProSense system outweigh the risks for early-stage low-risk invasive breast cancer, based on comprehensive data including the ICE3 study's 96.3% recurrence-free rate and 100% patient/physician satisfaction.
Epoch Partner Investments Limited, a significant shareholder, has provided a standby commitment to participate in the rights offering up to $5,000,000, ensuring a minimum gross proceeds of $5,000,000 from the offering.
The rights offering, if fully subscribed, is expected to provide approximately $9.4 million in net proceeds, which will be used to repay a bridge loan and support general corporate and working capital needs, extending the company's funding runway through May 31, 2026.

Negatives

The company had an accumulated deficit of $109.0 million and only $6.0 million in cash and cash equivalents as of March 31, 2025, indicating a significant need for capital.
Even if the rights offering is fully subscribed, the company will require additional capital to fund operations beyond May 31, 2026, posing a risk if further financing is not secured on acceptable terms.
The FDA has requested a post-market study for ProSense after marketing authorization is granted, which could delay the final marketing authorization decision and subsequent commercialization efforts.
The subscription rights are non-transferable, and there is no established public trading market for the pre-funded warrants and warrants, limiting liquidity for investors.
Shareholders who do not fully exercise their subscription rights will experience significant dilution of their ownership interest, especially due to Epoch's standby commitment.
The warrants issued in the offering are subject to a call feature, which could reduce their value if the company's share price significantly increases after FDA clearance.
The company does not intend to pay dividends, meaning shareholder returns depend solely on share price appreciation.
The company will incur substantial expenses of approximately $0.6 million for the rights offering, regardless of its success.

Risks

The company will require additional capital to fund operations beyond May 31, 2026, and failure to obtain financing on acceptable terms could delay or eliminate commercialization efforts.
Substantial expenses will be incurred in connection with the Rights Offering, which may not return adequate value if the offering is not consummated or successful.
The Rights Offering is not subject to a minimum offering amount, and proceeds may be insufficient to meet objectives, increasing risk to investors.
The Subscription Price may not be an indication of the fair value of the Ordinary Shares, Pre-Funded Warrants, or Warrants, and investors may not be able to sell at or above the Subscription Price.
The trading price of the company's Ordinary Shares may decline during or after the Rights Offering.
All exercises of Subscription Rights are irrevocable, even if unfavorable information emerges later.
The company may terminate, cancel, or amend the Rights Offering at any time prior to expiration.
Failure to act promptly and follow subscription instructions may result in rejection of the exercise of Subscription Rights.
If other shareholders do not exercise their Subscription Rights and Epoch performs its Standby Commitment, Epoch's ownership and control over the company will significantly increase.
No interest will be received on subscription funds, including any funds ultimately returned if the offering is canceled.
Personal checks used for payment may not clear in sufficient time to purchase Units.
The Subscription Rights are non-transferable, and there is no market for them.
The Rights Offering may cause the trading price of the company's Ordinary Shares to decrease due to potential dilution and future sales of underlying shares.
Shareholders with foreign addresses may experience delays in receiving rights offering materials, shortening their participation period.
The dealer-manager is not underwriting or placing the securities, and the Rights Offering may not be successful despite their services.
There is no public trading market for the Pre-Funded Warrants and Warrants, limiting liquidity.
Holders of Pre-Funded Warrants and Warrants have no rights as ordinary shareholders until exercise.
The Pre-Funded Warrants and Warrants are speculative in nature, and there is no assurance of profitability upon exercise.
The Warrants are subject to a call feature, which may reduce their value.
The company does not intend to pay dividends, so investment success depends on share price appreciation.
Operations in Israel are subject to political, economic, and military instability, including ongoing multi-front conflicts, which could disrupt business, supply chains, and employee availability.
Difficulty enforcing judgments against the company, its directors, and management due to their location in Israel, PRC, and Hong Kong, and the lack of reciprocal enforcement treaties with the U.S.

Future Outlook

The company anticipates conducting a post-market study for ProSense, expected to include a minimum of 400 patients at 25 sites, after receiving marketing authorization from the FDA. The final FDA marketing authorization decision is expected upon the CDRH's approval of this post-market study plan. The company expects the net proceeds from this Rights Offering, combined with existing cash, to fund operations through May 31, 2026, but acknowledges the need for further additional financing thereafter to support the establishment and expansion of its sales, marketing, and distribution infrastructure for ProSense commercialization.

Management Comments

Management intends to use the net proceeds from this Rights Offering, together with existing cash, cash equivalents, and short-term investments, to repay the Bridge Loan and for general corporate and working capital purposes.
The board of directors considered various factors in determining the Subscription Price, including the need to raise capital, current and historical trading prices, likelihood of participation, cost of capital from other sources, and the value of the unit components.

Industry Context

IceCure Medical operates in the medical device industry, specifically focusing on cryoablation technology for tumor treatment. The company's lead product, ProSense, targets a minimally invasive alternative to surgery for various tumors, including breast cancer. The ongoing FDA review process for ProSense for early-stage breast cancer highlights the significant regulatory hurdles and market potential within the oncology and minimally invasive surgery sectors. The need for a post-market study, even after a favorable advisory panel vote, reflects the FDA's cautious approach to new medical device approvals, particularly for cancer indications, and may set a precedent for similar technologies.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Status Declaration	The company is an 'emerging growth company' under the JOBS Act and a 'foreign private issuer' under the Exchange Act, allowing for reduced public company reporting requirements and exemptions from certain U.S. domestic issuer rules.	NA	Reduces reporting frequency and detail compared to U.S. domestic companies, potentially limiting information available to investors.
Board Structure	The board of directors consists of not less than five and not more than eleven directors, elected at annual or special general meetings.	NA	Standard corporate governance structure, with specific election requirements for external directors under Israeli law.
Shareholder Meeting Quorum	Quorum for general meetings requires at least two shareholders present in person, by proxy, written ballot, or electronic voting, representing at least 25% of total outstanding voting rights.	NA	Sets the minimum attendance for valid shareholder meetings.
Indemnification Policy	The company has entered into indemnification agreements with all directors and senior management, providing indemnification permitted under Israeli law and up to a certain amount, to the extent not covered by D&O insurance.	NA	Protects officers and directors from certain liabilities, potentially reducing personal risk but shifting some risk to the company.
Exclusive Forum Provision	Articles of association provide that U.S. federal district courts are the exclusive forum for Securities Act claims, unless the company consents otherwise.	NA	May limit shareholders' ability to choose a preferred judicial forum and could increase litigation costs, though enforceability is uncertain.

Legal Proceedings

The company highlights a general risk of becoming involved in intellectual property infringement actions or other litigation, which could adversely affect its business.

Related Party Transactions

On May 17, 2025, IceCure Medical Ltd. entered into an unsecured bridge loan agreement for $2,000,000 with Epoch Partner Investments Limited, which is considered a related party as it beneficially owns approximately 44.04% of the company's outstanding Ordinary Shares.
Epoch Partner Investments Limited has committed to participate in the Rights Offering by exercising its Basic Subscription Rights in full and Over-Subscription Privileges to purchase unsubscribed shares with an aggregate Subscription Price of up to $5,000,000. This standby commitment ensures a minimum capital raise from the offering and is a related-party transaction.

Stakeholder Impact

Shareholders: Face significant dilution risk if they do not fully exercise their subscription rights, especially due to the standby commitment from Epoch. Their investment success depends on share price appreciation as no dividends are expected. They also bear the risk of potential share price decline due to the offering and future sales of underlying securities.
Employees: Ten employees were called up for military service in connection with the multi-front conflict in Israel, with a risk of further call-ups, which could disrupt company operations.
Customers: Potential delays in product shipments due to supply chain disruptions caused by geopolitical conflicts in Israel (e.g., Red Sea attacks, port closures).

Next Steps

IceCure Medical Ltd. will present its post-market study plan for ProSense to the FDA, which is expected to include a minimum of 400 patients at 25 sites.
Upon the CDRH's approval of the post-market study plan, the FDA's final marketing authorization decision for ProSense for early-stage low-risk breast cancer is expected.
The company will proceed with the Rights Offering, distributing subscription rights and accepting exercises during the subscription period (dates to be determined).
The net proceeds from the Rights Offering will be used to repay the $2,000,000 Bridge Loan and for general corporate and working capital purposes.
The company will need to secure further additional financing beyond May 31, 2026, to fund its operations and commercialization efforts.

Key Dates

Date	Description
April 2024	Submitted data to the FDA along with a marketing authorization request to treat early-stage breast cancer for ProSense.
November 7, 2024	FDA convened a medical device advisory committee panel to review the De Novo marketing authorization request for ProSense, resulting in a favorable vote.
March 31, 2025	Financials reported as of this date, showing an accumulated deficit of $109.0 million and cash and cash equivalents of $6.0 million.
April 30, 2025	Announced conclusion of a meeting with the leadership of the Center for Devices and Radiological Health (CDRH) at the FDA, where FDA requested a post-market study.
May 17, 2025	Entered into an unsecured bridge loan agreement with Epoch Partner Investments Limited for $2,000,000.
May 31, 2026	Expected date through which existing cash and net proceeds from the Rights Offering will fund operating expenses and capital expenditure requirements.
June 13, 2025	Last sale price of Ordinary Shares on Nasdaq was $0.97 per share; 58,693,428 Ordinary Shares were issued and outstanding.
June 15, 2025	Israel launched a preemptive strike targeting military and nuclear infrastructure inside Iran; Israel temporarily closed its airspace and ceased all port activity related to commercial shipments.
June 16, 2025	Date of filing the F-1 Registration Statement.

Keywords

IceCure Medical, Rights Offering, F-1 Filing, Cryoablation, ProSense, Medical Device, FDA Approval, Capital Raise, Equity Offering, Warrants, Pre-Funded Warrants, Dilution, Corporate Finance, SEC Filing, Israel, Healthcare Technology, Tumor Treatment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.